Takeda Pharmaceutical Co. has offered to pay more than $2.2 billion to resolve claims it hid cancer risks related to its Actos diabetes medicine in what would be one of the largest U.S. settlements of patient lawsuits targeting drugs or devices, three people familiar with the matter said.
Officials at Asia's largest drugmaker proposed to settle more than 8,000 lawsuits in federal and state courts in the United States, said the people, who asked not to be identified as they weren't authorized to speak publicly on the offer.
Such a deal would amount to a payment of about $275,000 for each case. Any settlement would be the first in the three years of litigation over Actos.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.